Reduction in exacerbation of COPD in patients of advanced age using the Japanese kampo medicine dai-kenchu-to

A retrospective cohort study

Taisuke Jo, Nobuaki Michihata, Hayato Yamana, Yusuke Sasabuchi, Hiroki Matsui, Hirokazu Urushiyama, Akihisa Mitani, Yasuhiro Yamauchi, Kiyohide Fushimi, Takahide Nagase, Hideo Yasunaga

Research output: Contribution to journalArticle

Abstract

Purpose: Patients with symptomatic COPD are recommended to use inhaled bronchodilators containing long-acting muscarinic receptor antagonists (LAMAs). However, bronchodilators may cause gastrointestinal adverse effects due to anticholinergic reactions, especially in advanced-age patients with COPD. Dai-kenchu-to (TU-100, Da Jian Zhong Tang in Chinese) is the most frequently prescribed Japanese herbal Kampo medicine and is often prescribed to control abdominal bloating and constipation. The purpose of this study was to evaluate the role of Dai-kenchu-to as a supportive therapy in advanced-age patients with COPD. Patients and methods: We used the Japanese Diagnosis Procedure Combination inpatient database and identified patients aged ≥75 years who were hospitalized for COPD exacerbation. We then compared the risk of re-hospitalization for COPD exacerbation or death between patients with and without Dai-kenchu-to using 1-to-4 propensity score matching. A Cox proportional hazards model was used to compare the two groups. We performed subgroup analyses for patients with and without LAMA therapy. Results: Patients treated with Dai-kenchu-to had a significantly lower risk of re-hospitalization or death after discharge; the HR was 0.82 (95% CI, 0.67–0.99) in 1-to-4 propensity score matching. Subgroup analysis of LAMA users showed a significant difference in re-hospitalization or death, while subgroup analysis of LAMA non-users showed no significant difference. Conclusion: Our findings indicate that Dai-kenchu-to may have improved the tolerability of LAMA in advanced-age patients with COPD and, therefore, reduced the risk of re-hospitalization or death from COPD exacerbation. Dai-kenchu-to may be recommended as a useful supportive therapy for advanced-age patients with COPD.

Original languageEnglish
Pages (from-to)129-139
Number of pages11
JournalInternational Journal of COPD
Volume14
DOIs
Publication statusPublished - 2019 Jan 1
Externally publishedYes

Fingerprint

Kampo Medicine
Chronic Obstructive Pulmonary Disease
Cohort Studies
Retrospective Studies
Muscarinic Antagonists
Muscarinic Receptors
Hospitalization
Propensity Score
Bronchodilator Agents
dai-kenchu-to
Herbal Medicine
Cholinergic Antagonists
Constipation
Proportional Hazards Models
Inpatients
Therapeutics

Keywords

  • Herbal medicine
  • Muscarinic receptor antagonists
  • Propensity score
  • Survival analysis
  • TU-100

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Reduction in exacerbation of COPD in patients of advanced age using the Japanese kampo medicine dai-kenchu-to : A retrospective cohort study. / Jo, Taisuke; Michihata, Nobuaki; Yamana, Hayato; Sasabuchi, Yusuke; Matsui, Hiroki; Urushiyama, Hirokazu; Mitani, Akihisa; Yamauchi, Yasuhiro; Fushimi, Kiyohide; Nagase, Takahide; Yasunaga, Hideo.

In: International Journal of COPD, Vol. 14, 01.01.2019, p. 129-139.

Research output: Contribution to journalArticle

Jo, T, Michihata, N, Yamana, H, Sasabuchi, Y, Matsui, H, Urushiyama, H, Mitani, A, Yamauchi, Y, Fushimi, K, Nagase, T & Yasunaga, H 2019, 'Reduction in exacerbation of COPD in patients of advanced age using the Japanese kampo medicine dai-kenchu-to: A retrospective cohort study', International Journal of COPD, vol. 14, pp. 129-139. https://doi.org/10.2147/COPD.S181916
Jo, Taisuke ; Michihata, Nobuaki ; Yamana, Hayato ; Sasabuchi, Yusuke ; Matsui, Hiroki ; Urushiyama, Hirokazu ; Mitani, Akihisa ; Yamauchi, Yasuhiro ; Fushimi, Kiyohide ; Nagase, Takahide ; Yasunaga, Hideo. / Reduction in exacerbation of COPD in patients of advanced age using the Japanese kampo medicine dai-kenchu-to : A retrospective cohort study. In: International Journal of COPD. 2019 ; Vol. 14. pp. 129-139.
@article{cdb7f7d7e5e94c3fbcd5e542068ab02e,
title = "Reduction in exacerbation of COPD in patients of advanced age using the Japanese kampo medicine dai-kenchu-to: A retrospective cohort study",
abstract = "Purpose: Patients with symptomatic COPD are recommended to use inhaled bronchodilators containing long-acting muscarinic receptor antagonists (LAMAs). However, bronchodilators may cause gastrointestinal adverse effects due to anticholinergic reactions, especially in advanced-age patients with COPD. Dai-kenchu-to (TU-100, Da Jian Zhong Tang in Chinese) is the most frequently prescribed Japanese herbal Kampo medicine and is often prescribed to control abdominal bloating and constipation. The purpose of this study was to evaluate the role of Dai-kenchu-to as a supportive therapy in advanced-age patients with COPD. Patients and methods: We used the Japanese Diagnosis Procedure Combination inpatient database and identified patients aged ≥75 years who were hospitalized for COPD exacerbation. We then compared the risk of re-hospitalization for COPD exacerbation or death between patients with and without Dai-kenchu-to using 1-to-4 propensity score matching. A Cox proportional hazards model was used to compare the two groups. We performed subgroup analyses for patients with and without LAMA therapy. Results: Patients treated with Dai-kenchu-to had a significantly lower risk of re-hospitalization or death after discharge; the HR was 0.82 (95{\%} CI, 0.67–0.99) in 1-to-4 propensity score matching. Subgroup analysis of LAMA users showed a significant difference in re-hospitalization or death, while subgroup analysis of LAMA non-users showed no significant difference. Conclusion: Our findings indicate that Dai-kenchu-to may have improved the tolerability of LAMA in advanced-age patients with COPD and, therefore, reduced the risk of re-hospitalization or death from COPD exacerbation. Dai-kenchu-to may be recommended as a useful supportive therapy for advanced-age patients with COPD.",
keywords = "Herbal medicine, Muscarinic receptor antagonists, Propensity score, Survival analysis, TU-100",
author = "Taisuke Jo and Nobuaki Michihata and Hayato Yamana and Yusuke Sasabuchi and Hiroki Matsui and Hirokazu Urushiyama and Akihisa Mitani and Yasuhiro Yamauchi and Kiyohide Fushimi and Takahide Nagase and Hideo Yasunaga",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/COPD.S181916",
language = "English",
volume = "14",
pages = "129--139",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Reduction in exacerbation of COPD in patients of advanced age using the Japanese kampo medicine dai-kenchu-to

T2 - A retrospective cohort study

AU - Jo, Taisuke

AU - Michihata, Nobuaki

AU - Yamana, Hayato

AU - Sasabuchi, Yusuke

AU - Matsui, Hiroki

AU - Urushiyama, Hirokazu

AU - Mitani, Akihisa

AU - Yamauchi, Yasuhiro

AU - Fushimi, Kiyohide

AU - Nagase, Takahide

AU - Yasunaga, Hideo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Patients with symptomatic COPD are recommended to use inhaled bronchodilators containing long-acting muscarinic receptor antagonists (LAMAs). However, bronchodilators may cause gastrointestinal adverse effects due to anticholinergic reactions, especially in advanced-age patients with COPD. Dai-kenchu-to (TU-100, Da Jian Zhong Tang in Chinese) is the most frequently prescribed Japanese herbal Kampo medicine and is often prescribed to control abdominal bloating and constipation. The purpose of this study was to evaluate the role of Dai-kenchu-to as a supportive therapy in advanced-age patients with COPD. Patients and methods: We used the Japanese Diagnosis Procedure Combination inpatient database and identified patients aged ≥75 years who were hospitalized for COPD exacerbation. We then compared the risk of re-hospitalization for COPD exacerbation or death between patients with and without Dai-kenchu-to using 1-to-4 propensity score matching. A Cox proportional hazards model was used to compare the two groups. We performed subgroup analyses for patients with and without LAMA therapy. Results: Patients treated with Dai-kenchu-to had a significantly lower risk of re-hospitalization or death after discharge; the HR was 0.82 (95% CI, 0.67–0.99) in 1-to-4 propensity score matching. Subgroup analysis of LAMA users showed a significant difference in re-hospitalization or death, while subgroup analysis of LAMA non-users showed no significant difference. Conclusion: Our findings indicate that Dai-kenchu-to may have improved the tolerability of LAMA in advanced-age patients with COPD and, therefore, reduced the risk of re-hospitalization or death from COPD exacerbation. Dai-kenchu-to may be recommended as a useful supportive therapy for advanced-age patients with COPD.

AB - Purpose: Patients with symptomatic COPD are recommended to use inhaled bronchodilators containing long-acting muscarinic receptor antagonists (LAMAs). However, bronchodilators may cause gastrointestinal adverse effects due to anticholinergic reactions, especially in advanced-age patients with COPD. Dai-kenchu-to (TU-100, Da Jian Zhong Tang in Chinese) is the most frequently prescribed Japanese herbal Kampo medicine and is often prescribed to control abdominal bloating and constipation. The purpose of this study was to evaluate the role of Dai-kenchu-to as a supportive therapy in advanced-age patients with COPD. Patients and methods: We used the Japanese Diagnosis Procedure Combination inpatient database and identified patients aged ≥75 years who were hospitalized for COPD exacerbation. We then compared the risk of re-hospitalization for COPD exacerbation or death between patients with and without Dai-kenchu-to using 1-to-4 propensity score matching. A Cox proportional hazards model was used to compare the two groups. We performed subgroup analyses for patients with and without LAMA therapy. Results: Patients treated with Dai-kenchu-to had a significantly lower risk of re-hospitalization or death after discharge; the HR was 0.82 (95% CI, 0.67–0.99) in 1-to-4 propensity score matching. Subgroup analysis of LAMA users showed a significant difference in re-hospitalization or death, while subgroup analysis of LAMA non-users showed no significant difference. Conclusion: Our findings indicate that Dai-kenchu-to may have improved the tolerability of LAMA in advanced-age patients with COPD and, therefore, reduced the risk of re-hospitalization or death from COPD exacerbation. Dai-kenchu-to may be recommended as a useful supportive therapy for advanced-age patients with COPD.

KW - Herbal medicine

KW - Muscarinic receptor antagonists

KW - Propensity score

KW - Survival analysis

KW - TU-100

UR - http://www.scopus.com/inward/record.url?scp=85060034688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060034688&partnerID=8YFLogxK

U2 - 10.2147/COPD.S181916

DO - 10.2147/COPD.S181916

M3 - Article

VL - 14

SP - 129

EP - 139

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -